CONNECT WITH US
HealthTech

HealthTech

Gubra looks beyond metabolism, hopes for first portfolio company this year

Endpoints News logo

Published on

Add as a preferred source on Google
Gubra looks beyond metabolism, hopes for first portfolio company this year

Den­mark's Gubra looks be­yond me­tab­o­lism, hopes for first port­fo­lio com­pa­ny this year

The Copen­hagen-based drug­mak­er Gubra’s present is most­ly about obe­si­ty. Its fu­ture will need to be about a much broad­er pipeline.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Fer­ring to ac­quire ovary-in-a-dish start­up Ga­me­to for up to $1.38B October 27, 2026

Be­yond the can­cer vac­cine, how did Mer­ck’s on­col­o­gy pipeline do at ES­MO? October 26, 2026

EGFR-mu­tant lung can­cer is an ADC bat­tle­ground, with Chi­na lead­ing the charge October 26, 2026

Post-Makary FDA wins over in­vestors, but not sci­en­tists or Big Phar­ma: Sig­nal Sur­vey

Arti­va to wind down af­ter two pa­tient deaths in au­toim­mune cell ther­a­py tri­als



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.